Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Free cash flow
Biogen Inc.'s free cash flow for fiscal 2025 was $2.0B, down 19.7% from $2.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.5B. Over the past ten years it has ranged from $1.2B (fiscal 2023) to $6.4B (fiscal 2019); the current reading is higher than 27% of that period. Biogen Inc. ranks 14th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $2.0B | (19.74%) |
| FY2024 | $2.5B | 103.57% |
| FY2023 | $1.2B | (28.31%) |
| FY2022 | $1.7B | (48.75%) |
| FY2021 | $3.4B | (8.56%) |
| FY2020 | $3.7B | (42.61%) |
| FY2019 | $6.4B | 20.89% |
| FY2018 | $5.3B | 104.84% |
| FY2017 | $2.6B | (32.94%) |
| FY2016 | $3.9B | 18.35% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $273.0M | (54.06%) |
| Mar 2026 | $594.3M | 31.57% |
| Dec 2025 | $451.7M | (63.01%) |
| Sep 2025 | $1.2B | 809.16% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi compare | $14.5B |
| GILD Gilead Sciences, Inc. compare | $12.9B |
| BMY Bristol Myers Squibb Company compare | $11.4B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| GSK GSK PLC Sponsored ADR compare | $7.6B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
| BIIB Biogen Inc. | $2.5B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement